These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 20854087)

  • 1. Biclonal follicular lymphoma: histological, clinical and molecular characteristics.
    Noriega MF; De Brasi C; Narbaitz M; Rodríguez A; Slavutsky I
    Pathology; 2010; 42(6):598-601. PubMed ID: 20854087
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
    McLaughlin P; Hagemeister FB; Rodriguez MA; Sarris AH; Pate O; Younes A; Lee MS; Dang NH; Romaguera JE; Preti AH; McAda N; Cabanillas F
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):37-41. PubMed ID: 11225999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
    Luminari S; Marcheselli L; Sacchi S; Pozzi S; Bari A; Ilariucci F; Stelitano C; Angrilli F; Lazzaro A; Baldini L
    Cancer; 2009 May; 115(9):1906-13. PubMed ID: 19248044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
    Sacchi S; Pozzi S; Marcheselli R; Federico M; Tucci A; Merli F; Orsucci L; Liberati M; Vallisa D; Brugiatelli M;
    Cancer; 2007 Jul; 110(1):121-8. PubMed ID: 17503433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival.
    Bishton MJ; Rule S; Wilson W; Turner D; Patmore R; Clifton-Hadley L; McMillan A; Lush R; Haynes A
    Br J Haematol; 2020 Aug; 190(4):545-554. PubMed ID: 32150649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
    Lü SQ; Yang JM; Song XM; Chen L; Zhang WP; Ni X; Xu XQ; Wang JM
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):710-2. PubMed ID: 18246806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma.
    Ha CS; Cabanillas F; Lee MS; Tucker SL; McLaughlin P; Rodriguez MA; Younes A; Romaguera JE; Mesina OM; Cox JD
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):188-93. PubMed ID: 16111588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of mitoxantrone in the treatment of indolent lymphomas.
    Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL
    Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma.
    Crawley CR; Foran JM; Gupta RK; Rohatiner AZ; Summers K; Matthews J; Micallef IN; Radford JA; Johnson SA; Johnson PW; Sweetenham JW; Lister TA
    Ann Oncol; 2000 Jul; 11(7):861-5. PubMed ID: 10997815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
    Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA
    Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection and quantification of MBR/JH2 t(14;18) BCL-2 gene rearrangement in follicular lymphoma using a combined real-time polymerase chain reaction assay.
    Csernák E; Tóth E; Melegh Z; Schneider T; Rosta A; Szentirmay Z
    Haematologica; 2006 Jun; 91(6):858-9. PubMed ID: 16704964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
    Janikova A; Koristek Z; Vinklarkova J; Pavlik T; Sticha M; Navratil M; Kral Z; Vasova I; Mayer J
    Exp Hematol; 2009 Nov; 37(11):1266-73. PubMed ID: 19654036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.
    Montoto S; Moreno C; Domingo-Doménech E; Estany C; Oriol A; Altés A; Besalduch J; Pedro C; Gardella S; Escoda L; Asensio A; Vivancos P; Galán P; de Sevilla AF; Ribera JM; Briones J; Colomer D; Campo E; Montserrat E; López-Guillermo A;
    Haematologica; 2008 Feb; 93(2):207-14. PubMed ID: 18223288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transformation of follicular lymphoma to precursor B-cell lymphoblastic lymphoma with c-myc gene rearrangement as a critical event.
    Young KH; Xie Q; Zhou G; Eickhoff JC; Sanger WG; Aoun P; Chan WC
    Am J Clin Pathol; 2008 Jan; 129(1):157-66. PubMed ID: 18089500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Follicular lymphoma].
    Illés A; Krenács L; Borbényi Z
    Orv Hetil; 2003 Nov; 144(46):2253-61. PubMed ID: 14702920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of molecular remission in follicular lymphoma.
    Dührsen U; Hüttmann A; Dürig J
    J Clin Oncol; 2010 Oct; 28(30):e613; author reply e614. PubMed ID: 20713852
    [No Abstract]   [Full Text] [Related]  

  • 17. LightCycler-based quantitative real-time PCR monitoring of patients with follicular lymphoma receiving rituximab in combination with conventional or high-dose cytotoxic chemotherapy.
    Martin S; Fischer C; Free M; Kurreck B; Stockinger H; Fenk R; Arnold C; Kliszewski S; Meckenstock G; Haas R; Kronenwett R
    Eur J Haematol; 2005 Apr; 74(4):282-92. PubMed ID: 15777339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Follicular lymphomas].
    García-Conde J; Tormo M; Terol MJ; Benet I
    Sangre (Barc); 1997 Jun; 42(3):243-5. PubMed ID: 9381271
    [No Abstract]   [Full Text] [Related]  

  • 19. [Evaluation of the clinical effectivity and toxicity of the FDN regimen (fludarabin, mitoxantron, dexamethason) in patients with follicular lymphoma].
    Oborilová A; Mayer J; Korístek Z; Hofmanová Z; Vásová I; Navrátil M; Vinklárková J; Muzikárová M; Klabusay M; Matuska M
    Cas Lek Cesk; 2004; 143(10):685-90. PubMed ID: 15584619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).
    Morschhauser F; Mounier N; Sebban C; Brice P; Solal-Celigny P; Tilly H; Feugier P; Fermé C; Copin MC; Lamy T
    Cancer; 2010 Sep; 116(18):4299-308. PubMed ID: 20549824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.